Medesis Pharma Extends Collaboration in Biopharm Sector
Medesis Pharma has signed a collaboration agreement with the French Commission for Atomic Energy and Alternative Energies
Medesis Pharma, a biopharmaceutical company represented in France and Canada, has signed a collaboration agreement with the French Commission for Atomic Energy and Alternative Energies (Commissariat à l'énergie atomique et aux énergies alternatives, CEA) on the development of compounds designed to remove radioactive/toxic metal contaminants from the body.
Medesis Pharma is targeting the defense markets and the civil nuclear industry (especially governmental stocks of decorporation products for civil protection in the vicinity of nuclear power plants). At present, there are no appropriate marketed products to use on a broad population for decorporation of plutonium and cesium, and there is no treatment for the decorporation of uranium, according to the company.
"Here at Medesis Pharma, we are delighted to extend and formalize our collaboration with CEA - simply the best possible partner for many opportunities in this part of the pharmaceutical market," commented Pharma Medesis' CEO Jean-Claude Maurel.
Meanwhile, Eric Quémeneur (Program and Research Exploitation Director in the CEA's Life Sciences Department) welcomed the opportunity to jointly develop original compounds in under-explored therapeutic areas.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
